Development work will focus on a new costimulatory domain M83, which is an alternative to the more commonly used CD28 and 4-1BB domains. Its main technology is its M-STIM platform, which is derived from multiple costimulatory domains. In vitro preclinical data indicate that M83-based CAR T cells may be more efficacious in solid tumors than traditional CAR T cells.

FastBack Bio launches with technology licensed from the laboratory of Lishan Su, PhD, at the University of North Carolina at Chapel Hill. Su will continue to support development of the M83 platform through sponsored research and as an adviser to FastBack Bio.

FastBack Bio will be the first company with access to Inceptor Bio's advanced manufacturing platform (AMP+). AMP+ is designed to be a scalable manufacturing facility that provides expertise and capacity for critical viral vector and cell therapy operations.

Inceptor Bio was established in 2020 to pursue a diversified portfolio of cell therapy platforms across multiple cell types, including CAR T, CAR macrophage, and NK/NK-T cells.

Inceptor Bio to establish cell and gene therapy company portfolio
Inceptor Bio has raised $26 million in seed funding to create a portfolio of companies focused on developing next-generation cell and gene therapies...